Bortezomib and Th alidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up

Štork, Martin; Sandecká, Viera; Boichuk, Ivanna; Adam, Zdeněk; Krejčí, Marta; Brožová, Lucie; Ševčı́ková, Sabina; Pour, Luděk

doi:10.14735/amko2019445

Cited by 2 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The phase three clinical trial of Tacchetti et al confirmed that the combined regimen of bortezomib and thalidomide was superior to the chemotherapy regimen alone. 21 Stork et al 22 believe that bortezomib combined with thalidomide has an obvious short-term effect, and the long-term follow-up has verified that the combination with thalidomide provides additional advantages for the OS of patients. Jung’s study 23 has confirmed that thalidomide + dexamethasone-based regimen has great advantages in patients with recurrent/refractory MM (RRMM).…”

Section: Discussionmentioning

confidence: 99%

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma

Man²,

Li³

2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To evaluate the clinical efficacy of thalidomide combined with PAD regimen in patients with multiple myeloma (MM). Methods: It was a Clinical comparative study. A total of 120 patients with MM were admitted at Beijing Aerospace General Hospital from September 2020 to June 2022 randomly divided into two groups, with 60 patients in each group. The study group was treated with thalidomide combined with a PAD regimen (bortezomib, doxorubicin and dexamethasone), while the control group with a PAD regimen alone. After treatment, the therapeutic effect, adverse drug reactions, bone metabolic markers such as serum alkaline phosphatase (ALP) and osteocalcin (OCN) before and after treatment, as well as T-lymphocyte subsets CD3+, CD4+, CD8+ and CD4+/CD8+ levels before and after treatment were compared and analyzed between the two groups. Results: The total efficacy in the study group was 90%, which was significantly higher than 70% in the control group (p= 0.00). The incidence of adverse drug reactions was 40% in the study group and 38% in the control group, without statistically significant difference (p= 0.85). After treatment, ALP and OCN levels in the study group were significantly higher than those in the control group (ALP, p= 0.01; OCN, p= 0.00), and CD3+, CD4+ and CD4+/CD8+ in the study group also increased significantly compared with those in the control group (CD3+, p= 0.02; CD4+, p= 0.00; CD4+/CD8+, p= 0.00). Conclusion: Thalidomide combined with a PAD regimen is definitely effective in patients with MM, it can obviously improve immune function and bone salt metabolism, with no increase in adverse reactions but high safety and effectiveness. doi: https://doi.org/10.12669/pjms.39.5.6815 How to cite this: Wang Y, Man Q, Li C. Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma. Pak J Med Sci. 2023;39(5):---------. doi: https://doi.org/10.12669/pjms.39.5.6815 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 99%